Long-term outcome in kidney transplant patients with hepatitis C (HCV) infection

Susan Orloff, C. A. Stempel, T. L. Wright, S. J. Tomlanovich, J. C. Amend, P. G. Stock, J. S. Melzer, F. Vincenti

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

To assess the prevalence and long-term impact of HCV on kidney transplant recipients, we assayed 716 pre-transplant sera using a first-generation ELISA. The anti-HCV positive sera were confirmed by a 6-antigen radioimmunoassay (RIA). Patients were followed up for 5 years. Graft survival, function, evidence of chemical hepatitis (AST > 2 X normal), patient mortality and cause of death were evaluated. The prevalence of anti-HCV antibody was 10.3%. In the 638 patients who were followed up for 5 years, there were no differences in graft function, graft survival, overall mortality, or death from sepsis or liver disease. Peak AST levels were significantly higher in anti-HCV positive patients compared to anti-HCV negative patients. At 5 years, the AST levels remained significantly higher in the anti-HCV positive group, however, this was only 6 U/l > normal. Liver biopsies performed 3 to 7 years post-transplant in 80% of anti-HCV positive patients with chemical hepatitis showed 12% CAH, 50% mild hepatitis and 38% normal histology. Six (9.7%) patients seroconverted from anti-HCV positive to anti-HCV negative 2 to 5 years post-transplant. The presence of anti-HCV does not appear to alter long-term patient or graft survival, and histologic evidence of severe chronic liver disease was rare in anti-HCV positive patients with chemical hepatitis. From these results, the presence of anti-HCV antibody should not preclude kidney transplantation.

Original languageEnglish (US)
Pages (from-to)119-124
Number of pages6
JournalClinical Transplantation
Volume9
Issue number2
StatePublished - 1995
Externally publishedYes

Fingerprint

Hepatitis C
Transplants
Kidney
Infection
Hepatitis
Graft Survival
Hepatitis C Antibodies
Liver Diseases
Mortality
Serum
Kidney Transplantation
Radioimmunoassay
Cause of Death
Sepsis
Histology
Chronic Disease
Enzyme-Linked Immunosorbent Assay
Biopsy
Antigens
Liver

Keywords

  • Hepatitis C infection
  • Kidney transplantation

ASJC Scopus subject areas

  • Immunology
  • Transplantation

Cite this

Orloff, S., Stempel, C. A., Wright, T. L., Tomlanovich, S. J., Amend, J. C., Stock, P. G., ... Vincenti, F. (1995). Long-term outcome in kidney transplant patients with hepatitis C (HCV) infection. Clinical Transplantation, 9(2), 119-124.

Long-term outcome in kidney transplant patients with hepatitis C (HCV) infection. / Orloff, Susan; Stempel, C. A.; Wright, T. L.; Tomlanovich, S. J.; Amend, J. C.; Stock, P. G.; Melzer, J. S.; Vincenti, F.

In: Clinical Transplantation, Vol. 9, No. 2, 1995, p. 119-124.

Research output: Contribution to journalArticle

Orloff, S, Stempel, CA, Wright, TL, Tomlanovich, SJ, Amend, JC, Stock, PG, Melzer, JS & Vincenti, F 1995, 'Long-term outcome in kidney transplant patients with hepatitis C (HCV) infection', Clinical Transplantation, vol. 9, no. 2, pp. 119-124.
Orloff S, Stempel CA, Wright TL, Tomlanovich SJ, Amend JC, Stock PG et al. Long-term outcome in kidney transplant patients with hepatitis C (HCV) infection. Clinical Transplantation. 1995;9(2):119-124.
Orloff, Susan ; Stempel, C. A. ; Wright, T. L. ; Tomlanovich, S. J. ; Amend, J. C. ; Stock, P. G. ; Melzer, J. S. ; Vincenti, F. / Long-term outcome in kidney transplant patients with hepatitis C (HCV) infection. In: Clinical Transplantation. 1995 ; Vol. 9, No. 2. pp. 119-124.
@article{4f29623acfe243848e1139ae0326075b,
title = "Long-term outcome in kidney transplant patients with hepatitis C (HCV) infection",
abstract = "To assess the prevalence and long-term impact of HCV on kidney transplant recipients, we assayed 716 pre-transplant sera using a first-generation ELISA. The anti-HCV positive sera were confirmed by a 6-antigen radioimmunoassay (RIA). Patients were followed up for 5 years. Graft survival, function, evidence of chemical hepatitis (AST > 2 X normal), patient mortality and cause of death were evaluated. The prevalence of anti-HCV antibody was 10.3{\%}. In the 638 patients who were followed up for 5 years, there were no differences in graft function, graft survival, overall mortality, or death from sepsis or liver disease. Peak AST levels were significantly higher in anti-HCV positive patients compared to anti-HCV negative patients. At 5 years, the AST levels remained significantly higher in the anti-HCV positive group, however, this was only 6 U/l > normal. Liver biopsies performed 3 to 7 years post-transplant in 80{\%} of anti-HCV positive patients with chemical hepatitis showed 12{\%} CAH, 50{\%} mild hepatitis and 38{\%} normal histology. Six (9.7{\%}) patients seroconverted from anti-HCV positive to anti-HCV negative 2 to 5 years post-transplant. The presence of anti-HCV does not appear to alter long-term patient or graft survival, and histologic evidence of severe chronic liver disease was rare in anti-HCV positive patients with chemical hepatitis. From these results, the presence of anti-HCV antibody should not preclude kidney transplantation.",
keywords = "Hepatitis C infection, Kidney transplantation",
author = "Susan Orloff and Stempel, {C. A.} and Wright, {T. L.} and Tomlanovich, {S. J.} and Amend, {J. C.} and Stock, {P. G.} and Melzer, {J. S.} and F. Vincenti",
year = "1995",
language = "English (US)",
volume = "9",
pages = "119--124",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Long-term outcome in kidney transplant patients with hepatitis C (HCV) infection

AU - Orloff, Susan

AU - Stempel, C. A.

AU - Wright, T. L.

AU - Tomlanovich, S. J.

AU - Amend, J. C.

AU - Stock, P. G.

AU - Melzer, J. S.

AU - Vincenti, F.

PY - 1995

Y1 - 1995

N2 - To assess the prevalence and long-term impact of HCV on kidney transplant recipients, we assayed 716 pre-transplant sera using a first-generation ELISA. The anti-HCV positive sera were confirmed by a 6-antigen radioimmunoassay (RIA). Patients were followed up for 5 years. Graft survival, function, evidence of chemical hepatitis (AST > 2 X normal), patient mortality and cause of death were evaluated. The prevalence of anti-HCV antibody was 10.3%. In the 638 patients who were followed up for 5 years, there were no differences in graft function, graft survival, overall mortality, or death from sepsis or liver disease. Peak AST levels were significantly higher in anti-HCV positive patients compared to anti-HCV negative patients. At 5 years, the AST levels remained significantly higher in the anti-HCV positive group, however, this was only 6 U/l > normal. Liver biopsies performed 3 to 7 years post-transplant in 80% of anti-HCV positive patients with chemical hepatitis showed 12% CAH, 50% mild hepatitis and 38% normal histology. Six (9.7%) patients seroconverted from anti-HCV positive to anti-HCV negative 2 to 5 years post-transplant. The presence of anti-HCV does not appear to alter long-term patient or graft survival, and histologic evidence of severe chronic liver disease was rare in anti-HCV positive patients with chemical hepatitis. From these results, the presence of anti-HCV antibody should not preclude kidney transplantation.

AB - To assess the prevalence and long-term impact of HCV on kidney transplant recipients, we assayed 716 pre-transplant sera using a first-generation ELISA. The anti-HCV positive sera were confirmed by a 6-antigen radioimmunoassay (RIA). Patients were followed up for 5 years. Graft survival, function, evidence of chemical hepatitis (AST > 2 X normal), patient mortality and cause of death were evaluated. The prevalence of anti-HCV antibody was 10.3%. In the 638 patients who were followed up for 5 years, there were no differences in graft function, graft survival, overall mortality, or death from sepsis or liver disease. Peak AST levels were significantly higher in anti-HCV positive patients compared to anti-HCV negative patients. At 5 years, the AST levels remained significantly higher in the anti-HCV positive group, however, this was only 6 U/l > normal. Liver biopsies performed 3 to 7 years post-transplant in 80% of anti-HCV positive patients with chemical hepatitis showed 12% CAH, 50% mild hepatitis and 38% normal histology. Six (9.7%) patients seroconverted from anti-HCV positive to anti-HCV negative 2 to 5 years post-transplant. The presence of anti-HCV does not appear to alter long-term patient or graft survival, and histologic evidence of severe chronic liver disease was rare in anti-HCV positive patients with chemical hepatitis. From these results, the presence of anti-HCV antibody should not preclude kidney transplantation.

KW - Hepatitis C infection

KW - Kidney transplantation

UR - http://www.scopus.com/inward/record.url?scp=0028949847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028949847&partnerID=8YFLogxK

M3 - Article

C2 - 7599400

AN - SCOPUS:0028949847

VL - 9

SP - 119

EP - 124

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 2

ER -